Atonco
ApprovedATONCO develops molecularly targeted therapeutic oncology solutions using Astatine-211 for better quality and longer life for cancer patients.
Founded
2019
Focus
AntibodiesBiologics
About
ATONCO develops molecularly targeted therapeutic oncology solutions using Astatine-211 for better quality and longer life for cancer patients.
FDA Approved Drugs
1LODOSYNNDAApr 25, 1977
Company Info
TypePrivate
Founded2019
LocationParis, France
StageApproved
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile